Wednesday, August 5, 2015

Ciclofilin gets U.S. patent allowance for cyclophilin inhibitor

Ciclofilin gets U.S. patent allowance for cyclophilin inhibitor

August 4, 2015 by · Leave a Comment 

Tweet Closely-held Ciclofilin Pharmaceuticals has received a notice of allowance for a U.S. patent that expands its portfolio of cyclosporine-based molecules for a variety of indications mediated through interaction with a family of host proteins called, cyclophilins. The company’s U.S. Patent Application Number 13/994,707 is entitled, “Cyclosporine Analogue Molecules Modified at Amino Acid 1 and […]

RBC starts Abivax at outperform

RBC starts Abivax at outperform

August 4, 2015 by · Leave a Comment 

Tweet RBC Dominion Securities has initiated coverage of Aviva SA (Euronext Paris: FR0012333284 – ABVX) with an “outperform, speculative risk” rating and a target price of €27. The stock closed at €20 on Monday. Abivax is involved in the development of therapeutic vaccines and antiviral agents designed to treat a broad array of infectious diseases. […]

biOasis data shows MTfp-I2S crosses BBB to CNS

biOasis data shows MTfp-I2S crosses BBB to CNS

August 4, 2015 by · Leave a Comment 

Tweet Bioasis Technologies (OTCQX:BIOAF; TSX-V:BTI) has assessed data in the knockout mouse model of Hunter syndrome performed in Padova, Italy, by a team led by Dr. Maurizio Scarpa of the Brains for Brain Foundation. This knockout mouse model of Hunter Syndrome showed that the Transcend fusion protein, MTfp-I2S, was able to cross the blood-brain barrier, […]

Doctors discuss importance of tear film osmolarity

Doctors discuss importance of tear film osmolarity

August 4, 2015 by · Leave a Comment 

Tweet In an Eyetube.net video segment of the CRST Journal Club (Cataract & Refractive Surgery Today), Dr. John Davidson, of Miramar Eye Specialists in Ventura County, CA, and Dr. Jay Pepose, of the Pepose Vision Institute in St. Louis, discuss the importance of optimizing the ocular surface prior to premium intraocular lens surgery. Dr. Pepose […]

Amarantus in CRADA deal for skin substitute

Amarantus in CRADA deal for skin substitute

August 4, 2015 by · Leave a Comment 

Tweet Amarantus BioScience Holdings (OTCQX:AMBS) has signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) and Rutgers University to expand the development of its autologous, full thickness, skin replacement product. Amarantus’ Engineered Skin Substitute (ESS) is being developed for the treatment of deep partial- and full-thickness burn […]

RBC starts ProMetic Life Sciences at outperform

RBC starts ProMetic Life Sciences at outperform

July 30, 2015 by · Leave a Comment 

Tweet RBC Dominion Securities has initiated coverage of ProMetic Life Sciences (OTCQX:PFSCF; TSX:PLI) with an “outperform, speculative risk” rating and price target of $3.50. The stock closed at $2.20 on Wednesday. Analyst Douglas Miehm writes that for more than 25 years, ProMetic has helped other biopharmaceutical companies bring drugs to market with its bioseparation technology, […]

HCW starts Semler Scientific at buy

HCW starts Semler Scientific at buy

July 29, 2015 by · Leave a Comment 

Tweet H.C. Wainwright has launched coverage of Semler Scientific (NASDAQ:SMLR) with a “buy” rating and a 12-month price target of $8. The stock closed at $3.20 on Tuesday. Semler is a medical diagnostics company that is marketing a patented device for the risk assessment of peripheral arterial disease (PAD) and other vascular conditions. Known as […]

Amarantus study of MSPrecise published in GENE

Amarantus study of MSPrecise published in GENE

July 29, 2015 by · Leave a Comment 

Tweet Data on Amarantus Diagnostics’ next generation sequencing molecular diagnostic test for multiple sclerosis, MSPrecise, has been published in the Elsevier journal, GENE. MSPrecise is a proprietary next-generation DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS). A blood-based version of the test is in development. “Given the early misdiagnoses that […]

Analysts raise price target for LeMaitre Vascular

Analysts raise price target for LeMaitre Vascular

July 29, 2015 by · Leave a Comment 

Tweet Canaccord Genuity and Roth Capital Partners have raised their price targets for LeMaitre Vascular (NASDAQ:LMAT) to $14.50 from $13, and to $14 from $11, respectively, after the company set another record sales quarter. The stock closed at $11.24 on Tuesday. “We continue to view LeMaitre as one of the most undervalued small-cap stocks in […]

Roth starts Tracon Pharma at buy

Roth starts Tracon Pharma at buy

July 29, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Tracon Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $18 price target, calling the company an intriguing play in the $16-billion anti-VEGF market. The stock closed at $12.58 on Tuesday. Tracon is developing an antibody targeting the endoglin receptor. Endoglin is essential to the process of new blood […]

Next Page »

Email Newsletters with Constant Contact
Google+